We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 21 for:    Copanlisib

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

This study is currently recruiting participants.
Verified October 2016 by Cancer Trials Ireland
Sponsor:
ClinicalTrials.gov Identifier:
NCT02705859
First Posted: March 11, 2016
Last Update Posted: October 18, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cancer Trials Ireland
  Purpose

This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer.

Patients with HER2 positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8).


Condition Intervention Phase
HER2 Positive Breast Cancer Drug: Copanlisib Drug: Trastuzumab Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib/II Clinical Trial of Copanlisib in Combination With Trastuzumab in Pretreated Recurrent or Metastatic HER2-positive Breast Cancer

Resource links provided by NLM:


Further study details as provided by Cancer Trials Ireland:

Primary Outcome Measures:
  • Maximum Tolerated Dose of copanlisib in combination with trastuzumab measured by the incidence of dose limiting toxicity (DLT) of copanlisib in combination with trastuzumab within the 1st cycle at each dose level. [ Time Frame: 1 year ]
  • Clinical Benefit Rate, defined as complete response (CR) or partial response (PR) at any time-point on the study; or stable disease (SD) lasting at least 24 weeks based on radiological assessment. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Incidences of adverse events and toxicities. [ Time Frame: 1.5 - 2 year ]
  • Overall survival [ Time Frame: 1.5 -2 year ]
  • Progression-Free Survival (PFS) assessed according to RECIST criteria version 1.1 [ Time Frame: 1.5-2 year ]
  • Time to Treatment Failure (TTF) is defined as time from registration to discontinuation of therapy or add-on of new anti-cancer therapy for any reason (including death, progression and toxicity). [ Time Frame: 1.5-2 year ]
  • Confirmed tumour response rate as assessed by RECIST criteria version 1.1. [ Time Frame: 1.5-2 year ]
  • Duration of response (DR) as assessed by RECIST criteria version 1.1. [ Time Frame: 1.5-2 year ]
  • To evaluate the safety and tolerability of this regimen as measured by incidence of adverse events reported and toxicity evaluation as per the NCI Common Terminology Criteria for Adverse Events (CTCAE version 4.0). [ Time Frame: 1.5-2 year ]
  • To assess the incidence of cardiotoxicity. Cardiac safety monitoring will include physical exam, (with NYHA functional classification for patients with diagnosed congestive heart failure) at each cycle, and MUGA scan or ECHO [ Time Frame: 1.5-2 year ]

Estimated Enrollment: 19
Study Start Date: April 2016
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Arm

This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.

Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8).

Drug: Copanlisib
Copanlisib is a novel small molecule PI3K inhibitor being evaluated for the treatment of a wide variety of advanced and refractory malignancies either as a single agent or in combination with other investigational agents.Copanlisib has potent and selective activity against all four Class I PI3K isoforms with IC50s of 0.5-6.4nM in biochemical assays. Notably, copanlisib shows excellent anti-tumour activity in pre-clinical models with an up-regulated PI3Kα pathway suggesting a particular role for it in PIK3CA mutated cancers.
Other Name: BAY80-6946
Drug: Trastuzumab
A humanised IgG1 monoclonal antibody
Other Name: Herceptin

Detailed Description:

Phase Ib One of three dose levels of copanlisib is assigned at registration according to the dose escalation scheme.

Phase II The copanlisib dose for the Phase II part of the trial will be based on the MTD established in the Phase Ib part of the study.

Clinical and laboratory parameters will be assessed to evaluate disease response and toxicity of study therapy.

Safety assessments will be performed throughout the study.

Efficacy assessments (radiological examination) will be performed on all patients every 8 weeks for the first 24 weeks and every 12 weeks thereafter.

Following baseline cardiac assessment, cardiac safety monitoring will include physical exam (with New York Heart Association (NYHA) functional classification for patients with diagnosed congestive heart failure) during each cycle, Multigated acquisition (MUGA) scan or Echocardiogram (ECHO) and 12 lead Electrocardiogram (ECG) within 7 days of Day 1 of every third cycle starting at cycle 3 (Cycle 3, Cycle 6, etc.).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients are eligible to be included in the study only if they meet all of the following criteria:

  1. Adult women ≥18 years of age with histologically confirmed, recurrent, or metastatic, HER2-positive breast cancer.

    Eligible recurrent disease is recurrent disease that is considered incurable by the treating oncologist. Many local only recurrences are treated with curative intent; a treatment plan with curative intent for a local only recurrence would indicate that the patient is not eligible for this clinical trial. A local only recurrence must be considered incurable by the treating oncologist for the patient to be eligible.

  2. Documented HER2 overexpression by local laboratory (IHC 3+ or FISH or CISH positive).
  3. At least one measurable lesion according to RECIST criteria (Version 1.1). Patients with bone only disease are not eligible.
  4. Patient has received at least one trastuzumab based or TDM1-based treatment regimen in the setting of metastatic disease or incurable locoregional recurrence. A trastuzumab based or TDM1-based treatment regimen is considered as any treatment regimen that includes trastuzumab or TDM1.

    Patients must have had at least 1 line of therapy for metastatic and/or incurable locoregional recurrent disease to be eligible. A patient is eligible regardless of the period of time from adjuvant therapy so long as she has disease that is progressing after at least 1 line of trastuzumab-based therapy in the setting of metastatic disease and/or incurable locoregional recurrence.

  5. Disease progression during or following the most recent anticancer therapy.
  6. ECOG performance status ≤2.
  7. Life expectancy of at least 3 months.
  8. Availability of fresh tissue and/or archival tumour tissue at screening.
  9. Women of childbearing potential must agree to use a highly effective method of contraception when sexually active. This applies from signing of the informed consent form until at least 100 days after the last study drug administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable), intrauterine device (IUD), intrauterine hormone releasing system (IUS), bilateral tubal occlusion, successfully vasectomised partner and sexual abstinence. In addition, the use of condoms by patients or their partners is required unless the woman has had a hysterectomy.
  10. Adequate baseline laboratory values collected no more than 14 days before starting study treatment:

    Total bilirubin ≤1.5 x ULN (<3 x ULN for patients with liver involvement). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x ULN for patients with liver involvement from breast cancer).

    Lipase ≤1.5 x ULN. Glomerular filtration rate (GFR) ≥30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula. If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the later result is within acceptable range, it may be used to fulfil the inclusion criteria instead.

    International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1.5 x ULN. Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of these patients (Day 15 of Cycle 1 and Day 1 of each cycle) will be performed until INR/PTT is stable based on a measurement that is predose as defined by the local standard of care.

    Platelet count ≥75 x 109/L. For patients with breast cancer bone marrow infiltration, platelet count ≥50 x 109/L.

    Haemoglobin (Hb) ≥8 g/dL. Absolute neutrophil count (ANC) ≥1 x 109/L. For patients with malignant bone marrow infiltration, ANC count ≥0.75 x 109/L.

    Fasting blood glucose <125 mg/dL (≤6.9 mmol/L) if not diabetic or <160 mg/dL (≤8.9 mmol/L) if diabetic

  11. Left ventricular ejection fraction (LVEF), above the Institutions lower limit of normal, as determined by ECHO or MUGA.
  12. Patients must have recovered from clinically significant side effects associated with prior radiotherapy and chemotherapy.

    5.1.1 Additional criteria for Phase II:

  13. PIK3CA mutation confirmed by central laboratory.
  14. Phase Ib subjects (who are confirmed PIK3CA mutation carriers) must have been treated at the MTD in order to proceed with enrolment/registration to the Phase II study.

Exclusion Criteria:

Patients who meet any of the following criteria at the time of screening will be excluded from study registration:

  1. Known breast cancer involvement of the brain, unless adequately controlled as documented by baseline CT Scan (or PET CT/MRI if as per RECIST 1.1) that has not progressed since previous scans and that does not require corticosteroids for management of CNS symptoms
  2. Congestive heart failure >New York Heart Association (NYHA) class II.
  3. Unstable angina (angina symptoms at rest), new onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before registration. Uncontrolled arterial hypertension (systolic blood pressure >160 mmHg or diastolic pressure >90 mmHg despite optimal medical management).
  4. Uncontrolled Type I or II diabetes mellitus. Defined as HbA1c >8.5% or a fasting plasma glucose >8.9 mmol/L as determined during screening laboratory assessments.
  5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before registration.
  6. Non-healing wound, ulcer, or bone fracture.
  7. Active, clinically serious infections >CTCAE Grade 2 (CTCAE v4.0).
  8. Known history of human immunodeficiency virus (HIV) infection.
  9. Hepatitis B (HBV) or hepatitis C (HCV). All patients must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus laboratorial panel. Patients who test positive for HBsAg or HBcAb will be eligible if they are negative for HBV DNA; patients who test positive for anti-HCV antibody will be eligible if they are negative for HCV RNA.
  10. Patients with seizure disorder requiring medication.
  11. Patients with evidence or history of bleeding diathesis. Any haemorrhage or bleeding event ≥CTCAE Grade 3 within 4 weeks prior to the start of study treatment.
  12. Proteinuria of CTCAE Grade 3 or higher.
  13. History or concurrent condition of interstitial lung disease of any severity, and/or severely impaired lung function (as judged by the investigator).
  14. Concurrent diagnosis of pheochromocytoma.
  15. Pregnant or breast feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment.
  16. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia, peripheral neuropathy, and bone marrow parameters.
  17. Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation.
  18. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  19. Any illness or medical conditions that are unstable or could jeopardize the safety of patients and their compliance in the study.
  20. Patients permanently withdrawn from study participation will not be allowed to re enter the study.

    5.2.1 Excluded previous therapies and medications:

  21. Treatment with investigational drugs other than PI3K inhibitors less than 28 days before start of treatment.
  22. Ongoing immunosuppressive therapy.
  23. Radiotherapy or immunotherapy/chemotherapy less than 4 weeks before start of treatment.
  24. Myeloid growth factors less than 7 days before start of treatment.
  25. Blood or platelet transfusion less than 7 days before start of treatment.
  26. Ongoing systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent. Previous corticosteroid therapy must be stopped or reduced to the allowed dose 7 days before performing the screening CT scan (or PET CT/MRI as per RECIST 1.1) and again prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de escalated to the minimum allowed dose before the screening. Patients may continue to use topical or inhaled corticosteroids.
  27. History of having received an allogeneic bone marrow or organ transplant.
  28. Major surgical procedure or significant traumatic injury (as judged by the investigator) less than 28 days before start of treatment. This does not include the study specific biopsy.
  29. Antiarrhythmic therapy (beta blockers or digoxin are permitted).
  30. Use of strong inhibitors of CYP3A4 is prohibited from Day 14 of Cycle 1 until the Safety follow up visit.
  31. Use of inducers of CYP3A4 is prohibited from Day 14 of Cycle 1 until the Safety follow up visit.

Zoledronate or denosumab for patients with bone metastasis is allowed.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02705859


Contacts
Contact: ICORG 60 Fitzwilliam Square +353 1 6677211
Contact: Prof Bryan Hennessy

Locations
Ireland
St Vincent's University Hospital Recruiting
Elm Park, Dublin 4, Ireland
Contact: Jo Ballott    +353 1 221 4000      
Principal Investigator: Prof John Crown         
Beaumont University Hospital Recruiting
Beaumont Road, Dublin 9, Ireland
Contact: Derval Kehily    +353 1 809 3000      
Principal Investigator: Prof Bryan Hennessy         
University Hospital Galway Not yet recruiting
Galway, Ireland
Contact: Mary Byrne         
Contact    +353 91 524 222      
Principal Investigator: Dr Maccon Keane         
Sponsors and Collaborators
Cancer Trials Ireland
  More Information

Responsible Party: Cancer Trials Ireland
ClinicalTrials.gov Identifier: NCT02705859     History of Changes
Other Study ID Numbers: ICORG 15-02
First Submitted: February 11, 2016
First Posted: March 11, 2016
Last Update Posted: October 18, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Antineoplastic Agents